Core Viewpoint - The stock of Jiangsu Hengrui Medicine Co., Ltd. (02617) surged nearly 14% following the announcement of positive clinical results for its core product, Tiengogatinib, published in a prestigious medical journal [1] Group 1: Clinical Results - Tiengogatinib demonstrated durable responses and extended survival in patients with cholangiocarcinoma during a Phase 2 exploratory clinical trial conducted in the United States [1] - The study results were published in "The Lancet Gastroenterology & Hepatology," which has an impact factor of 38.6 [1] - Researchers from the University of Texas MD Anderson Cancer Center highlighted the need for next-generation FGFR2 inhibitors, with Tiengogatinib being noted for its unique mechanism targeting FGFR [1] Group 2: Product Information - Tiengogatinib is an innovative multi-target small molecule kinase inhibitor developed independently by the company, currently in the registration clinical phase [1] - The drug targets tumor cells and improves the tumor microenvironment to exert anti-tumor effects [1] - Tiengogatinib has received orphan drug designation (ODD) and fast track designation from the FDA for cholangiocarcinoma treatment, and it is included in the breakthrough therapy list and priority review list by China's NMPA [1]
港股异动 | 药捷安康-B(02617)拉升近14% 近日宣布在《柳叶刀》子刊发表替恩戈替尼积极临床结果